Canadian Cardiovascular Society grading of angina pectoris

Global Empty Capsules Market Report 2022: Increasing Pharmaceutical Applications Driving 7.4% Annual Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Packaging, Pharmaceutical, Health, Manufacturing, Taste, COVID-19, American College of Cardiology, CVD, United Nations, United Kingdom, CAGR, World, American College, Prevalence, World Health Organization, Obesity, First Nations in Ontario, Cardiac rehabilitation, Canadian Cardiovascular Society grading of angina pectoris, Arthritis, Cardiovascular disease, Hypertension, Heart, Dietary supplement, Degenerative disease, Death, Research, Cancer, Capsule, Angina, American Heart Association, Incidence, Pharmaceutical industry, Cardiology, Growth

The "Empty Capsules Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Empty Capsules Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • Also, the growing geriatric population worldwide increases the demand for various therapy drugs and dietary supplements for better health outcomes.
  • In addition, rapid advancements in capsule delivery technologies are set to supplement the market growth.
  • However, ethical concerns, price fluctuations regarding gelatin materials, and stringent regulations in the pharmaceutical industry are expected to hamper the market growth.

The Global Empty Capsules Market Will Grow to USD 3,513 Million in 2026, with a CAGR of 7.4% - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Health, Pharmaceutical, Vitamin D, Mineral, Hypertension, Population Reference Bureau, Population, ACG Group, Death, CVD, Conditional sentence, Degenerative disease, Cardiovascular disease, Immunity, Gelatin, Awareness, American College of Cardiology, Dietary supplement, Vitamin, First Nations in Ontario, World, American Heart Association, Canadian Cardiovascular Society grading of angina pectoris, Incidence, COVID-19, Cancer, United Kingdom, American College, CAGR, Key, Research, Capsule, Taste, Cardiac rehabilitation, World Health Organization, Home, Prevalence, Obesity, Arthritis, CHI, Malnutrition, United Nations, CHF, Angina, Heart, Vaccine, Pharmaceutical industry, Video game, Cardiology, Growth

Empty Capsules Market is valued at approximately USD 2,289 million in 2020 and is expected to witness a revenue of USD 3,513 million in 2026, with a CAGR of 7.4% over the forecast period.

Key Points: 
  • Empty Capsules Market is valued at approximately USD 2,289 million in 2020 and is expected to witness a revenue of USD 3,513 million in 2026, with a CAGR of 7.4% over the forecast period.
  • The current COVID-19 pandemic is expected to positively impact the growth of the empty capsules market globally.
  • Thus, the COVID-19 pandemic surges the demand for nutraceuticals, which in turn is expected to boost the studied market growth.
  • Also, the growing geriatric population worldwide increases the demand for various therapy drugs and dietary supplements, for better health outcomes.

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

Retrieved on: 
Thursday, September 16, 2021
Risk, European Union, OH, Incidence, Heart, Adrenal insufficiency, FDA, Forward-looking statement, Investigational device exemption, Clinical trial, Health, Insurance, Marketing, Patient, Union, Company, Blood, Nasdaq, Intention, Private Securities Litigation Reform Act, Indian stock exchange, Muscle tissue, Regulatory affairs, Safety, Industry, Physician, Legislation, Growth, COVID-19, News, Angina, Conversation, Analysis, Perfusion, GLOBE, Investigational New Drug, Hospital, Christ Hospital, Management, TSX, Sale, Canadian Cardiovascular Society grading of angina pectoris, Pharmaceutical industry, Medical device

VANCOUVER and MINNEAPOLIS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial. 

Key Points: 
  • (Neovasc or the Company) ( Nasdaq , TSX : NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (IDE) regardingthe COSIRA-II IDE Clinical Trial.
  • The approval of the supplement is consistent with Neovascs internal target, and the Company remains on track to enroll the first patient in the trial late this year.
  • COSIRA-II is a randomized, sham-controlled trial investigating the safety and effectiveness of the Reducer for patients suffering from refractory angina.
  • FDA approval of the IDE Supplement is another important milestone for Neovasc, commented Lisa Becker, Vice President of Regulatory Affairs, Global Angina Therapies, at Neovasc.

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Retrieved on: 
Tuesday, August 17, 2021
Adrenal insufficiency, Blood, Intention, European Union, Food, Health, Hospital, Indian stock exchange, Safety, Risk, Christ Hospital, Canadian Cardiovascular Society, Union, Conversation, OH, Heart, Forward-looking statement, History, Sale, Regulation of tobacco by the U.S. Food and Drug Administration, Industry, Muscle tissue, Regulatory affairs, Legislation, Analysis, Incidence, Insurance, Canadian Cardiovascular Society grading of angina pectoris, Nasdaq, Perfusion, Angina, FDA, Company, European Heart Journal, Growth, Literature, GLOBE, CCS, Physician, Private Securities Litigation Reform Act, Marketing, Management, News, Patient, IDE, TSX, COVID-19, Pharmaceutical industry, Medical device

(Neovasc or the Company) ( Nasdaq , TSX : NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • (Neovasc or the Company) ( Nasdaq , TSX : NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA).
  • The proposed primary endpoint of the trial is change in exercise tolerance testing time via a modified Bruce protocol between baseline and 6-month follow-up.
  • The study is planned to enroll approximately 380 patients at up to 50 sites primarily in the United States.
  • (1) Submission of the IDE Supplement is an important step as we work towards commencing the trial this year.

Neovasc Comments on EuroIntervention Article

Retrieved on: 
Monday, April 19, 2021
Canadian Cardiovascular Society, Angina, XC2, CCS, Cardiology, Medicine, Clinical medicine, Canadian Cardiovascular Society grading of angina pectoris

Angina severity reflected by the Canadian Cardiovascular Society (CCS) grading improved from a mean of 3.2\xc2\xb10.5 to 1.6\xc2\xb10.8, (p

Key Points: 
  • Angina severity reflected by the Canadian Cardiovascular Society (CCS) grading improved from a mean of 3.2\xc2\xb10.5 to 1.6\xc2\xb10.8, (p
  • Only very limited differences in anti-anginal medications were recorded, with a mean of 1.9\xc2\xb11.1 drugs per patient at baseline vs 1.8\xc2\xb11.1 at follow-up (p=0.77).
  • Prof. Stefan Verheye, M.D., PhD, Antwerp Cardiovascular Center Middelheim, Antwerp, Belgium, said, \xe2\x80\x9cIt is reassuring to see the consistent improvements in chest pain in patients treated with the Reducer.
  • It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing.

Neovasc Comments on Journal of the American Heart Association Publication

Retrieved on: 
Friday, February 5, 2021
Acute pain, Angina, Cardiology, Canadian Cardiovascular Society grading of angina pectoris

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 5, 2021) - Neovasc , Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Journal of the American Heart Association has published an article entitled, "Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina" .

Key Points: 
  • Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 5, 2021) - Neovasc , Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Journal of the American Heart Association has published an article entitled, "Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina" .
  • The prestigious journal is the official publication of the American Heart Association, and the article offers important insights into the burden of angina on both patients and healthcare systems.
  • The study found that patients suffering from angina had worse outcomes and higher rates of healthcare utilization than patients without angina.
  • Importantly, patients with more severe classes of angina, CCS III & IV, had markedly worse outcomes than CCS I & II.

Neovasc Comments on Journal of the American Heart Association Publication

Retrieved on: 
Friday, February 5, 2021
Acute pain, Angina, Cardiology, Renal angina, Canadian Cardiovascular Society grading of angina pectoris

VANCOUVER and MINNEAPOLIS, Feb. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the Journal of the American Heart Association has published an article entitled, Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina .

Key Points: 
  • VANCOUVER and MINNEAPOLIS, Feb. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the Journal of the American Heart Association has published an article entitled, Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina .
  • The prestigious journal is the official publication of the American Heart Association, and the article offers important insights into the burden of angina on both patients and healthcare systems.
  • The retrospective analysis of veterans in the United States utilized natural language processing to identify over 14,000 patients suffering from angina.
  • The study found that patients suffering from angina had worse outcomes and higher rates of healthcare utilization than patients without angina.